GeneOne Life Science, Inc.
Founded in 1976 and listed on the KOSPI in 1987, GeneOne Life Science is a biologics CDMO and drug developer that co-developed the MERS DNA vaccine GLS-5300 with Inovio.
As of 2026-10-10, GeneOne Life Science, Inc. has 35 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Products & technology
- cGMP Plasmid DNARaw material for gene therapies and DNA vaccines (clinical/nonclinical use)
Clinical trials
data.go.kr7 MFDS clinical trial authorisations · 2013–2021 (Phase 1 5 · Phase 2 1 · Phase 1/2a 1)
- Phase 2GLS-10272021-09-08
6 trial sites
- Phase 1GLS-61002021-05-20
1 trial site
- Phase 1/2aGLS-53102020-12-04
5 trial sites
- Phase 1GLS-61502018-02-02
2 trial sites
- Phase 1GLS-53002017-09-14
2 trial sites
- Phase 1GLS-61502014-09-26
2 trial sites
- Phase 1GLS-61502013-10-18
2 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 2 · Unknown · 2023-12 · NCT04060316
Phase 1 · Unknown · 2022-05 · NCT05182567
Phase 1 · Unknown · 2021-11 · NCT05085639
Phase 2 · Completed · 2021-05 · NCT04590547
Phase 1/2 · Completed · 2020-12 · NCT04673149
Phase 2 · Terminated · 2020-06 · NCT04408183
Phase 1 · Completed · 2018-09 · NCT03674125
Phase 1/2 · Completed · 2018-08 · NCT03721718
Phase 1 · Completed · 2016-08 · NCT02887482
Phase 1 · Completed · 2016-07 · NCT02809443
Show 3 more trials
Phase 1 · Completed · 2016-02 · NCT02670187
Phase 1 · Completed · 2014-01 · NCT02027116
Phase 1 · Completed · 2010-08 · NCT01184976
R&D and key agreements
Source: DART corporate disclosureGLS-5300 · 중동호흡기증후군(MERS) · 임상1상(해외), 임상1/2a상(국내) 완료(2020년 4월 종료) · A DNA vaccine to prevent MERS coronavirus infection; Phase 1 results showed strong safety and immune response, with immune responses comparable to recovered MERS patients maintained 60 weeks after vaccination.
mRNA 생산 플랫폼 · 생산공정 스케일업 진행중 · Preparing mRNA vaccine and therapeutic CDMO services based on mRNA production technology licensed from HMRI.
Key disclosures
KRX KIND via OpenDARTShow 44 more events
Publications
PubMed · affiliation-matched- Delivery of DNA-encoded vaccines and proteins in mice using cutaneous suction-mediated transfection.
FEBS open bio · 2026-07 · Lallow EO, Brandtjen I, Mo Y 외 10
- The Role of the CLIC/GEEC Endocytic Pathway for Mechanophysical Transfection of DNA.
The journal of gene medicine · 2025-12 · Weaver S, Lallow EO, Kyker-Snowman K 외 6
- Microneedle arrays coated with Middle East respiratory syndrome coronavirus DNA vaccine via electrospray deposition.
Soft matter · 2025-04 · Park SH, Shah IR, Jhumur NC 외 10
- Immunogenicity and protection of a triple repeat domain III mRNA vaccine against Zika virus.
Vaccine · 2025-01 · Lee YS, Cheong MS, Lee J 외 24
- Efficient electrospray deposition of surfaces smaller than the spray plume.
Nature communications · 2023-08 · Park SH, Lei L, D'Souza D 외 10
- Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy.
Antibodies (Basel, Switzerland) · 2023-07 · Chung C, Kudchodkar SB, Chung CN 외 5
- Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
Vaccine · 2023-06 · Kim WJ, Roberts CC, Song JY 외 16
- DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond.
Vaccines · 2023-05 · Maslow JN, Kwon I, Kudchodkar SB 외 6
- Preclinical safety assessment of the suction-assisted intradermal injection of the SARS-CoV-2 DNA vaccine candidate pGO-1002 in white rabbit.
Archives of toxicology · 2023-04 · Oh S, Jang MS, Jung KJ 외 8
- Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023-03 · Kim WJ, Roberts CC, Song JY 외 21
Show 25 more publications
- Molecular distribution in intradermal injection for transfer and delivery of therapeutics.
Frontiers in drug delivery · 2023-01 · Lallow EO, Busha KJ, Park SH 외 11
- Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases.
Methods in molecular biology (Clifton, N.J.) · 2022-01 · Xu Z, Ho M, Bordoloi D 외 10
- Novel suction-based in vivo cutaneous DNA transfection platform.
Science advances · 2021-11 · Lallow EO, Jhumur NC, Ahmed I 외 13
- Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.
Genes & cancer · 2021-01 · Bordoloi D, Xiao P, Choi H 외 8
- Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing.
Translational medicine communications · 2021-01 · Muthumani K, Xu Z, Jeong M 외 3
- IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.
Journal of hepatology · 2020-07 · Han JW, Sung PS, Hong SH 외 11
- Zika Virus: A Brief History and Review of Its Pathogenesis Rediscovered.
Methods in molecular biology (Clifton, N.J.) · 2020-01 · Maslow JN, Roberts CC
- Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
The Lancet. Infectious diseases · 2019-09 · Modjarrad K, Roberts CC, Mills KT 외 32
- Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets.
Nature communications · 2019-08 · Kwak JE, Kim YI, Park SJ 외 20
- Zika Vaccine Development-Current Progress and Challenges for the Future.
Tropical medicine and infectious disease · 2019-07 · Maslow JN
- Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
The Journal of infectious diseases · 2019-07 · Tebas P, Kraynyak KA, Patel A 외 18
- Severe fever and thrombocytopenia syndrome virus infection: Considerations for vaccine evaluation of a rare disease.
Human vaccines & immunotherapeutics · 2019-01 · Maslow JN, Kwon JJ, Mikota SK 외 3
- Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization.
The Journal of infectious diseases · 2019-01 · de La Vega MA, Piret J, Griffin BD 외 16
- Irisin Exerts Inhibitory Effect on Adipogenesis Through Regulation of Wnt Signaling.
Frontiers in physiology · 2019-01 · Ma EB, Sahar NE, Jeong M 외 1
- The cost and challenge of vaccine development for emerging and emergent infectious diseases.
The Lancet. Global health · 2018-12 · Maslow JN
- Assay Challenges for Emerging Infectious Diseases: The Zika Experience.
Vaccines · 2018-10 · Roberts CC, Maslow JN
- Herpes Zoster DNA Vaccines with IL-7 and IL-33 Molecular Adjuvants Elicit Protective T Cell Immunity.
Immune network · 2018-10 · Kim AR, Park J, Kim JH 외 6
- Expression of the glutamine metabolism-related proteins glutaminase 1 and glutamate dehydrogenase in canine mammary tumours.
Veterinary and comparative oncology · 2018-06 · Ryu JE, Park HK, Choi HJ 외 5
- Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.
Human vaccines & immunotherapeutics · 2017-12 · Maslow JN
- DNA vaccination protects mice against Zika virus-induced damage to the testes.
Nature communications · 2017-06 · Griffin BD, Muthumani K, Warner BM 외 31
- Humoral and Cellular Immunogenicity Induced by Avian Influenza A (H7N9) DNA Vaccine in Mice.
Infection & chemotherapy · 2017-06 · Choi EJ, Lee HS, Noh JY 외 6
- Epidemiology and characteristics of Escherichia coli sequence type 131 (ST131) from long-term care facility residents colonized intestinally with fluoroquinolone-resistant Escherichia coli.
Diagnostic microbiology and infectious disease · 2017-03 · Han JH, Garrigan C, Johnston B 외 10
- Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection.
Scientific reports · 2017-03 · Lee H, Jeong M, Oh J 외 11
- Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2.
Cancer gene therapy · 2016-10 · Kim H, Danishmalik SN, Hwang H 외 7
- In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.
NPJ vaccines · 2016-01 · Muthumani K, Griffin BD, Agarwal S 외 26
Patents
KIPRIS · applicant-matchedRejected · 2023-12 · Application 1020230183033
US · Published · 2022-11 · Application 19118769
PCT · Published · 2022-11 · Application PCT/KR2022/017717
PCT · Published · 2022-11 · Application PCT/KR2022/017601
US · Published · 2022-10 · Application 18702303
PCT · Published · 2022-10 · Application PCT/IB2022/060499
PCT · Published · 2022-09 · Application PCT/KR2022/013454
Rejected · 2022-09 · Application 1020220113558
- Subsidiary: VGXI, Inc.COMPOSITIONS COMPRISING HIGH CONCENTRATION OF BIOLOGICALLY ACTIVE MOLECULES AND PROCESSES FOR PREPARING THE SAME
US · Published · 2022-09 · Application 17903751
US · Published · 2022-04 · Application 18284300
Show 35 more patents
PCT · Published · 2022-04 · Application PCT/KR2022/005362
Abandoned · 2021-11 · Application 1020210157389
Registered · 2021-08 · Application 1020210113088
US · Published · 2021-07 · Application 18016666
EP · Published · 2021-07 · Application 21841541.2
PCT · Published · 2021-07 · Application PCT/KR2021/009290
Registered · 2021-07 · Application 1020210094405
US · Published · 2021-04 · Application 17236918
Registered · 2021-04 · Application 1020210048441
US · Published · 2020-12 · Application 17786310
EP · Published · 2020-12 · Application 20902222.7
Rejected · 2020-12 · Application 1020227024295
US · Published · 2020-01 · Application 17256547
- Subsidiary: VGXI, Inc.Compositions comprising high concentration of biologically active molecules and processes for preparing the same
US · Registered · 2019-07 · Application 16517985
CN · Published · 2019-06 · Application 201980043842.6
PCT · Published · 2019-06 · Application PCT/KR2019/007920
- Subsidiary: VGXI, Inc.LYSIS COIL APPARATUS AND USES THEREOF FOR ISOLATION AND PURIFICATION OF POLYNUCLEOTIDES
CN · Published · 2019-05 · Application 201980036018.8
- Subsidiary: VGXI, Inc.LYSIS COIL APPARATUS AND USES THEREOF FOR ISOLATION AND PURIFICATION OF POLYNUCLEOTIDES
US · Published · 2019-05 · Application 17058747
- Subsidiary: VGXI, Inc.LYSIS COIL APPARATUS AND USES THEREOF FOR ISOLATION AND PURIFICATION OF POLYNUCLEOTIDES
EP · Published · 2019-05 · Application 19812601.3
- Subsidiary: VGXI, Inc.LYSIS COIL APPARATUS AND USES THEREOF FOR ISOLATION AND PURIFICATION OF POLYNUCLEOTIDES
PCT · Published · 2019-05 · Application PCT/US2019/034840
Rejected · 2019-01 · Application 1020190009553
Registered · 2018-06 · Application 1020180074418
US · Registered · 2015-11 · Application 15606087
JP · Published · 2015-11 · Application 29547366
CN · Published · 2015-06 · Application 201580070052.9
US · Published · 2015-06 · Application 15520282
EP · Published · 2015-06 · Application 15852539.4
PCT · Published · 2015-06 · Application PCT/KR2015/006043
Withdrawn · 2015-05 · Application 1020150067337
Registered · 2014-11 · Application 1020140167371
Registered · 2014-10 · Application 1020140142531
EP · Registered · 2013-04 · Application 13721573.7
- Subsidiary: VGXI, Inc.COMPOSITION COMPRISING HIGH CONCENTRATION OF BIOLOGICALLY ACTIVE MOLECULES AND PROCESSES FOR PREPARING THE SAME
EP · Registered · 2008-05 · Application 08756211.2
- Subsidiary: VGXI, Inc.Devices and methods for biomaterial production
EP · Registered · 2004-05 · Application 10075640.2
- Subsidiary: VGXI, Inc.DEVICES AND METHODS FOR BIOMATERIAL PRODUCTION
EP · Registered · 2004-05 · Application 04753608.1
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive4
- OpenAIOAI-SearchBot34
- PerplexityPerplexityBot6
- AnthropicClaudeBot2
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for GeneOne Life Science, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition